Bruton’s Tyrosine Kinase: An Exciting New Target for Treatment of B-Cell Malignancies
Inhibition of Bruton’s tyrosine kinase (Btk) is emerging as a promising mechanism for targeting B-cell malignancies such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) where the B-cell antigen receptor (BCR) is thought to possess an oncogenic role.
